{"id":"insulin-glargine-300u-ml","safety":{"commonSideEffects":[{"rate":null,"effect":"Hypoglycemia"},{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Weight gain"},{"rate":null,"effect":"Lipodystrophy"}]},"_chembl":{"chemblId":"CHEMBL1201497","moleculeType":"Protein"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Insulin glargine is a recombinant human insulin analog modified to have an extended duration of action (up to 24 hours). It binds to insulin receptors on muscle, fat, and liver cells, facilitating glucose uptake and storage while suppressing hepatic glucose production. The 300U/mL formulation is a concentrated version allowing smaller injection volumes for patients requiring high insulin doses.","oneSentence":"Insulin glargine is a long-acting basal insulin that binds to insulin receptors on cells to promote glucose uptake and reduce blood glucose levels.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:49:10.433Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 1 diabetes mellitus"},{"name":"Type 2 diabetes mellitus"}]},"trialDetails":[{"nctId":"NCT04760626","phase":"PHASE3","title":"A Research Study to Compare a New Weekly Insulin, Insulin Icodec Used With DoseGuide App, and Daily Insulins in People With Type 2 Diabetes Who Have Not Used Insulin Before","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2021-03-01","conditions":"Diabetes Mellitus, Type 2","enrollment":1085},{"nctId":"NCT03389490","phase":"PHASE4","title":"Toujeo Versus NPH Self-titration Study","status":"COMPLETED","sponsor":"Elaine Chow","startDate":"2018-01-01","conditions":"Diabetes Mellitus, Type 2","enrollment":50},{"nctId":"NCT02738151","phase":"PHASE4","title":"Efficacy and Safety of Toujeo® Versus Tresiba® in Insulin-Naive Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Oral Antihyperglycemic Drug(s) ± GLP-1 Receptor Agonist","status":"COMPLETED","sponsor":"Sanofi","startDate":"2016-05-19","conditions":"Diabetes Mellitus, Type 2","enrollment":929}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":6,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["HOE901-U300","Toujeo"],"phase":"marketed","status":"active","brandName":"Insulin glargine, 300U/mL","genericName":"Insulin glargine, 300U/mL","companyName":"Sanofi","companyId":"sanofi","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Insulin glargine is a long-acting basal insulin that binds to insulin receptors on cells to promote glucose uptake and reduce blood glucose levels. Used for Type 1 diabetes mellitus, Type 2 diabetes mellitus.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}